A Retrospective Cohort Study on Primary Cutaneous Amyloidosis

Launched by ARMY MEDICAL UNIVERSITY, CHINA · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called primary cutaneous amyloidosis, which causes skin problems and itching. Researchers want to find out if a combination of two medications, tocilizumab tablets and acitretin capsules, works better than just acitretin alone in relieving itching and improving skin symptoms. They will also check if this combination leads to any unexpected health issues. The study will last 16 weeks, and participants will visit the clinic every four weeks for check-ups.

To be eligible for this study, participants need to be at least 18 years old and have a confirmed diagnosis of primary cutaneous amyloidosis. They should not have any serious underlying health issues or infectious diseases. Participants will take the medications daily and will be monitored closely to see how their symptoms change. It's important to know that they will also be assessed for any side effects during the study. If you or someone you know fits these criteria and is interested, this trial could be an opportunity to help improve treatment options for this skin condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old, without infectious diseases such as "hepatitis B" and "tuberculosis" and major underlying diseases (gender not limited);
• • "Outpatient Diagnosis" includes "primary cutaneous amyloidosis", "macular amyloidosis" or "lichen amyloidosis";
• • Visited the outpatient department for PCA treatment for 4 times or more;
• • The medication record shows "Avastin Capsules" and/or "Tofacitinib Citrate";
• • The medical record fully records baseline characteristics, medication dosage, efficacy assessment and adverse events.
• Exclusion Criteria:
• • Nodular amyloidosis or combined with other types of amyloidosis (such as systemic amyloidosis);
• • During the study period, other immunosuppressants (such as glucocorticoids, methotrexate) or biologics were used;
• • Incomplete medical records such as demographic data, laboratory parameters, prescription administration and patient prognosis, as well as irregular treatment, etc.